{"id":2052,"date":"2021-08-13T20:35:52","date_gmt":"2021-08-13T20:35:52","guid":{"rendered":"http:\/\/wp.cov19longhaulfoundation.org\/?p=2052"},"modified":"2021-08-13T20:35:52","modified_gmt":"2021-08-13T20:35:52","slug":"covid-19-science-update-released-june-4-2021-edition-92","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=2052","title":{"rendered":"COVID-19 Science Update released: June 4, 2021 Edition 92"},"content":{"rendered":"\n<p>Authors: <strong>From the Office of the Chief Medical Officer, CDC COVID-19 Response, and the CDC Library, Atlanta GA.\u00a0Intended for use by public health professionals responding to the COVID-19 pandemic.<\/strong><\/p>\n\n\n\n<p><strong>PEER-REVIEWED<\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2107456\" target=\"_blank\" rel=\"noreferrer noopener\">Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents.external icon\u00a0Frenck\u00a0<em>et al.\u00a0<\/em>NEJM<\/a> (May 27, 2021).<\/strong><\/p>\n\n\n\n<p><strong>Key findings:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\" style=\"font-size:24px\"><li>Vaccine efficacy was 100% (95% CI 75.3%-100%) in 12- to 15-year-olds.<ul><li>There were no cases in the vaccinated group compared with 16 cases among the placebo group, 7 or more days after dose 2.<\/li><\/ul><\/li><li>Compared with baseline, geometric mean neutralizing antibody titers were 118.3-fold higher 1 month after dose 2.<\/li><li>Vaccine reactions were mainly transient, mild to moderate, and similar to a comparator group of 16\u201325-year-olds.<ul><li>Injection-site pain was reported by 79% to 86%, fatigue was reported by 60% to 66%, and headache was reported by 55% to 65% of participants (Figure).<\/li><\/ul><\/li><\/ul>\n\n\n\n<p style=\"font-size:24px\"><strong>Methods<\/strong>: A randomized, placebo-controlled, observer-blinded trial of Pfizer\/BioNTech BNT162b2 in 2,260 adolescents 12\u201315 years old (1,129 received placebo). Efficacy of the vaccine was assessed based on confirmed SARS-CoV-2 infection with onset 7 or more days after dose 2. Reactogenicity events (assessed for 7 days after each dose) and unsolicited adverse events compared with 16\u201325 age group (n = 3,610). SARS-CoV-2 serum neutralization assays were performed.&nbsp;<em><u>Limitations<\/u><\/em><em>:&nbsp;<\/em>Racial and ethnic diversity of participants 12-15 years does not reflect the general US population; short (1 month) post-vaccination safety evaluation.<\/p>\n\n\n\n<p style=\"font-size:24px\"><strong>Implications<\/strong>: Vaccination of adolescents with BNT162b2 was safe and effective. Vaccinating adolescents will broaden community protection, and it will likely facilitate reintegration into society and resumption of in-person learning.<\/p>\n\n\n\n<p><strong>Figure:<\/strong><img decoding=\"async\" src=\"https:\/\/www.cdc.gov\/library\/covid19\/images\/june2021\/0604_FIG1.png\" alt=\"Graphs showing systemic events with 7 days after dose 1 or dose 2 of vaccine or placebo\"><a href=\"https:\/\/www.cdc.gov\/library\/covid19\/06042021_covidupdate.html#\">resize iconView Larger<\/a><\/p>\n\n\n\n<p style=\"font-size:24px\"><em>Note:<\/em>&nbsp;Adapted from Frenck&nbsp;<em>et al<\/em>. Systemic events reported within 7 days after receiving dose 1 (top) or dose 2 (bottom) of vaccine or placebo. 1 participant in the 12-to-15-year-old group had a fever with a temperature &gt;40\u00b0C after dose 1. From the New England Journal of Medicine, Frenck&nbsp;<em>et al<\/em>., Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. May 27, 2021, online ahead of print. Copyright \u00a9 2021 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.kidney-international.org\/article\/S0085-2538(21)00509-3\/fulltext\" target=\"_blank\" rel=\"noreferrer noopener\">Occurrence of severe COVID-19 in vaccinated transplant patientsexternal icon<\/a>. Caillard&nbsp;<em>et al.&nbsp;<\/em>Kidney International. (May 21, 2021).<\/strong><\/p>\n\n\n\n<p><strong>Key findings:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\" style=\"font-size:24px\"><li>55 solid organ transplant recipients developed COVID-19 after receiving 2 doses of mRNA vaccine.<ul><li>Symptoms began a median of 22 days after the second vaccine dose (Figure).<\/li><li>15 cases required hospitalization; of these, 6 were admitted to an intensive care unit, and 3 died.<\/li><\/ul><\/li><li>Of 25 patients with post-vaccination serology, 24 were antibody negative; 1 was antibody positive but had low titers.<\/li><\/ul>\n\n\n\n<p class=\"has-large-font-size\">For More Information: <a href=\"https:\/\/www.cdc.gov\/library\/covid19\/06042021_covidupdate.ht\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.cdc.gov\/library\/covid19\/06042021_covidupdate.ht<\/a>ml<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Authors: From the Office of the Chief Medical Officer, CDC COVID-19 Response, and the CDC Library, Atlanta GA.\u00a0Intended for use by public health professionals responding to the COVID-19 pandemic. PEER-REVIEWED [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[979,22,981,1005,836,1000,890,607],"tags":[],"class_list":["post-2052","post","type-post","status-publish","format-standard","hentry","category-antibody-immune-system","category-antibody","category-anigen","category-bone-marrow","category-immune-system","category-natural-immunity","category-natural-immunity-immune-system","category-vaccine-news"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/2052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2052"}],"version-history":[{"count":0,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/2052\/revisions"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}